Working… Menu

Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04133155
Recruitment Status : Recruiting
First Posted : October 21, 2019
Last Update Posted : October 22, 2019
Bundang CHA Hospital
Ulsan University Hospital
Information provided by (Responsible Party):
Changhoon Yoo, Asan Medical Center

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 1, 2020
Estimated Study Completion Date : January 1, 2021